Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01353950 · ClinicalTrials.gov registry record
Costimulatory Molecules as Biomarkers in Cystic Fibrosis
A clinical trial, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- 40
- Enrollment target
NCT01353950: Completed study, sponsored by Oregon Health and Science University.
NCT01353950 is a clinical trial that has completed, run by Oregon Health and Science University. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01353950 has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the expression of a certain class of molecules, called costimulatory molecules, in humans with Cystic Fibrosis. Cystic Fibrosis is a genetic disorder which renders the lung susceptible to persistent inflammation which, at times, can worsen, resulting in accelerated decline in lung function and eventually death or transplant. Our goal is to determine if the levels of costimulatory markers can be used to predict exacerbation and subsequent lung function decline in subjects with Cystic Fibrosis.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2011-07 |
| Est. Completion | 2013-06 |
What the finished NCT01353950 record still lists
NCT01353950 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01353950 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01353950 about?
NCT01353950 is a clinical study titled "Costimulatory Molecules as Biomarkers in Cystic Fibrosis". The purpose of this study is to investigate the expression of a certain class of molecules, called costimulatory molecules, in humans with Cystic Fibrosis. Cystic Fibrosis is a genetic disorder which renders the lung susceptible to persistent inflammation which, at times, can worsen, resulting in ac...
What is the current status of trial NCT01353950?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2011-07. Estimated completion is 2013-06.
Who is sponsoring clinical trial NCT01353950?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia